Company Description
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform.
In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests.
The company was incorporated in 2011 and is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 4, 2018 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,021 |
| CEO | Dr. Helmy Eltoukhy Ph.D. |
Contact Details
Address: 3100 Hanover Street Palo Alto, California 94304 United States | |
| Phone | 855 698 8887 |
| Website | guardanthealth.com |
Stock Details
| Ticker Symbol | GH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001576280 |
| CUSIP Number | 40131M109 |
| ISIN Number | US40131M1099 |
| Employer ID | 45-4139254 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. AmirAli Talasaz Ph.D. | Co-Chief Executive Officer and Director |
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-Chief Executive Officer and Chairman |
| Michael Bell | Chief Financial Officer |
| Darya Chudova | Chief Technology Officer |
| John G. Saia J.D. | Chief Legal Officer and Corporate Secretary |
| Terilyn Juarez Monroe | Chief People Officer |
| Andy Ament | Senior Vice President of Operations |
| Kumud Kalia | Chief Information Officer |
| Zarak Khurshid | Vice President of Investor Relations |
| Gulshan Shaver J.D. | Senior Vice President of Legal Affairs and Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2025 | 144 | Filing |
| Apr 30, 2025 | 10-Q | Quarterly Report |
| Apr 30, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | 144 | Filing |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 9, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 144 | Filing |